News Conference News AHA 2019 Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS Todd Neale November 20, 2019
News Conference News AHA 2019 Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial Shelley Wood November 18, 2019
News Conference News AHA 2019 No Benefit of Colchicine in All-Comers PCI Shelley Wood November 17, 2019
News Conference News AHA 2019 Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT Yael L. Maxwell November 17, 2019
News Conference News AHA 2019 ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events Shelley Wood November 16, 2019
News Conference News AHA 2019 ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD Todd Neale November 16, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Conference News AHA 2019 More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA Michael O'Riordan November 14, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News AHA 2019 ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain Shelley Wood October 25, 2019
News Conference News TCT 2019 TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients Todd Neale October 03, 2019
News Conference News TCT 2019 GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients? Todd Neale September 30, 2019
News Conference News TCT 2019 Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk Michael O'Riordan September 29, 2019
News Conference News TCT 2019 Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA Michael O'Riordan September 28, 2019
News Conference News TCT 2019 Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT Michael O'Riordan September 27, 2019
News Conference News TCT 2019 Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT Caitlin E. Cox September 26, 2019
News Conference News TCT 2019 AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups Todd Neale September 26, 2019
News Conference News TCT 2019 Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients L.A. McKeown September 26, 2019
News Conference News TCT 2019 IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease Michael O'Riordan September 26, 2019
News Conference News TCT 2019 TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events Yael L. Maxwell September 26, 2019